NASDAQ:AKBA

Akebia Therapeutics (AKBA) Stock Price, News & Analysis

$1.37
0.00 (0.00%)
(As of 04/24/2024 ET)
Today's Range
$1.35
$1.40
50-Day Range
$1.35
$2.24
52-Week Range
$0.65
$2.48
Volume
1.51 million shs
Average Volume
4.29 million shs
Market Capitalization
$286.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Akebia Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
265.0% Upside
$5.00 Price Target
Short Interest
Bearish
6.40% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.35
Upright™ Environmental Score
News Sentiment
0.00mentions of Akebia Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$300,598 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.28) to ($0.19) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.41 out of 5 stars

Medical Sector

275th out of 909 stocks

Pharmaceutical Preparations Industry

119th out of 423 stocks

AKBA stock logo

About Akebia Therapeutics Stock (NASDAQ:AKBA)

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

AKBA Stock Price History

AKBA Stock News Headlines

Akebia Therapeutics Surges on FDA Approval for Anemia Treatment
Akebia Therapeutics Inc. (NASDAQ: AKBA) is a biopharmaceutical company specializing in developing treatments for chronic kidney diseases (CKD) and anemia
Akebia Therapeutics Surges on FDA Approval for Anemia Treatment
Akebia Therapeutics Inc. NASDAQ: AKBA is a biopharmaceutical company specializing in developing treatments for chronic kidney diseases (CKD) and anemia management for patients with CKD. The medical sector company addresses unmet needs in the segment.
The "Smart Money" Is Ready for May 1st Are You?
Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company.
The Hard Truth About Investing For Retirement
Here’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.
U.S. FDA approves Akebia's anemia drug
Akebia Awaits FDA Word On Second Crack At Vadadustat
Recap: Akebia Therapeutics Q4 Earnings
Akebia Therapeutics earnings: here's what Wall Street expects
Earnings Preview For Akebia Therapeutics
See More Headlines
Receive AKBA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akebia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/14/2024
Today
4/24/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AKBA
Employees
167
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.00
High Stock Price Target
$6.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+265.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-51,920,000.00
Pretax Margin
-26.68%

Debt

Sales & Book Value

Annual Sales
$194.62 million
Book Value
($0.16) per share

Miscellaneous

Free Float
201,332,000
Market Cap
$286.84 million
Optionable
Optionable
Beta
0.79
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

AKBA Stock Analysis - Frequently Asked Questions

Should I buy or sell Akebia Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akebia Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AKBA shares.
View AKBA analyst ratings
or view top-rated stocks.

What is Akebia Therapeutics' stock price target for 2024?

3 Wall Street analysts have issued 1 year price objectives for Akebia Therapeutics' shares. Their AKBA share price targets range from $4.00 to $6.00. On average, they predict the company's stock price to reach $5.00 in the next year. This suggests a possible upside of 265.0% from the stock's current price.
View analysts price targets for AKBA
or view top-rated stocks among Wall Street analysts.

How have AKBA shares performed in 2024?

Akebia Therapeutics' stock was trading at $1.24 at the start of the year. Since then, AKBA stock has increased by 10.5% and is now trading at $1.37.
View the best growth stocks for 2024 here
.

Are investors shorting Akebia Therapeutics?

Akebia Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 13,400,000 shares, an increase of 32.3% from the March 15th total of 10,130,000 shares. Based on an average daily volume of 4,530,000 shares, the short-interest ratio is presently 3.0 days.
View Akebia Therapeutics' Short Interest
.

When is Akebia Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our AKBA earnings forecast
.

How were Akebia Therapeutics' earnings last quarter?

Akebia Therapeutics, Inc. (NASDAQ:AKBA) posted its quarterly earnings data on Thursday, March, 14th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, meeting the consensus estimate of ($0.04). The biopharmaceutical company had revenue of $56.20 million for the quarter, compared to analyst estimates of $55.64 million. During the same period in the previous year, the company posted ($0.04) earnings per share.

What is John Butler's approval rating as Akebia Therapeutics' CEO?

28 employees have rated Akebia Therapeutics Chief Executive Officer John Butler on Glassdoor.com. John Butler has an approval rating of 97% among the company's employees. This puts John Butler in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Akebia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akebia Therapeutics investors own include Novavax (NVAX), Gilead Sciences (GILD), AbbVie (ABBV), Energy Transfer (ET), Micron Technology (MU), TherapeuticsMD (TXMD), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), NVIDIA (NVDA) and AT&T (T).

Who are Akebia Therapeutics' major shareholders?

Akebia Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.38%), Cannon Global Investment Management LLC (0.01%) and Compass Ion Advisors LLC (0.01%). Insiders that own company stock include David A Spellman, John P Butler, Michel Dahan, Nicole R Hadas, Steven C Gilman, Steven C Gilman, Steven Keith Burke and Violetta Cotreau.
View institutional ownership trends
.

How do I buy shares of Akebia Therapeutics?

Shares of AKBA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AKBA) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners